Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 7/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 7/20 | 0.44 |
| ▸ | RELA | Q04206 | 7/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10660414 | 1.00 | NAAA (0.49) | NAAAGAANFKB1NFKB2RELA | |
| SCHEMBL10665432 | 1.00 | NAAA (0.49) | NAAAGAANFKB1NFKB2RELA | |
| SCHEMBL17049788 | 1.00 | NAAA (0.49) | NAAAGAANFKB1NFKB2RELA | |
| SCHEMBL10832796 | 1.00 | NAAA (0.49) | NAAAGAANFKB1NFKB2RELA | |
| SCHEMBL10683017 | 1.00 | NAAA (0.49) | NAAAGAANFKB1NFKB2RELA | |
| SCHEMBL24187616 | 0.90 | GAA (0.47) | NAAAGAANFKB1NFKB2RELA | |
| SCHEMBL24187610 | 0.90 | GAA (0.47) | NAAAGAANFKB1NFKB2RELA | |
| SCHEMBL24187613 | 0.90 | GAA (0.47) | NAAAGAANFKB1NFKB2RELA | |
| SCHEMBL24187612 | 0.90 | GAA (0.47) | NAAAGAANFKB1NFKB2RELA | |
| SCHEMBL15621646 | 0.80 | IDO1 (0.47) | GAANFKB1NFKB2RELAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009580-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. | 2021-01-14 | — | — | US | disclosed |
| US-10815228-B2 | Aztreonam derivatives and uses thereof | ARIXA PHARMACEUTICALS, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| CN-111448182-A | Aztreonam derivative and application thereof | 阿里萨制药有限公司 | 2020-07-24 | — | — | CN | disclosed |
| US-20190211006-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-10280161-B2 | Aztreonam derivatives and uses thereof | ARIXA PHARMACEUTICALS, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| WO-2019070595-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| US-20190100516-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | ARIXA PHARMACEUTICALS, INC. | 2019-04-04 | — | — | US | disclosed |
| US-20140238939-A1 | IMMOBILIZATION OF ANTIMICROBIAL POLYMERS ON RO MEMBRANE TO REDUCE BIOFILM GROWTH AND BIOFOULING | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013110643-A1 | AMIDINE SUBSTITUTED BETA - LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | AICURIS GMBH & CO. KG (DE) | 2013-08-01 | — | — | WO | disclosed |
| US-4946838-A | BACTERICIDES HAVING STABILITY AND HYDROPHOBIC | E. R. SQUIBB & SONS, INC. (US) | 1990-08-07 | — | — | US | disclosed |
| US-4551277-A | 4-(3-Acylamino-2-oxo-1-azetidinyl)-4-oxo-2-butenoic acid | E. R. SQUIBB & SONS, INC. (US) | 1985-11-05 | — | — | US | disclosed |
| EP-0061765-B1 | BETA-LACTAMS | E.R. SQUIBB & SONS, INC. (US) | 1985-08-28 | — | — | EP | disclosed |
| US-4534896-A | 3-Acylamino-2-oxoazetidine-1-(β-oxopropionic acid) | E. R. SQUIBB & SONS, INC. (US) | 1985-08-13 | — | — | US | disclosed |
| US-4529698-A | Culturing Chromobacterium | E. R. SQUIBB & SONS, INC. (US) | 1985-07-16 | — | — | US | disclosed |
| EP-0138407-A1 | Azetidinones | E.R. Squibb & Sons, Inc. (US) | 1985-04-24 | — | — | EP | disclosed |
| US-4478749-A | AMINO ACID DERTIVATIVES ANTIBIOTICS | E. R. SQUIBB & SONS, INC. (US) | 1984-10-23 | — | — | US | disclosed |
| EP-0070024-A1 | The crystalline anhydrous form of (3S-(3 alpha(z),4 beta))-3-(((2-amino-4-thiazolyl)(1-carboxy-1-methylethoxy)-imino)-acetyl)-amino)-4-methyl-2-oxo-1-azetidinesulfonic acid, method for its preparation, mixture and pharmaceutical composition containing it | E.R. Squibb & Sons, Inc. (US) | 1983-01-19 | — | — | EP | disclosed |
| EP-0062876-A1 | 2-Oxo-1-(((substituted sulfonyl)amino)carbonyl)azetidines | E.R. Squibb & Sons, Inc. (US) | 1982-10-20 | — | — | EP | disclosed |
| EP-0061765-A1 | Beta-Lactams | E.R. SQUIBB & SONS, INC. (US) | 1982-10-06 | — | — | EP | disclosed |
| EP-0048953-A2 | Beta-lactam antibiotics | E.R. Squibb & Sons, Inc. (US) | 1982-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280161-B2 | Aztreonam derivatives and uses thereof | MGAM, ABCG2, SI | NAAA 44/4885GAA 17/4885NFKB1 2947/4885 |
| US-20190211006-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | MGAM, ABCG2, SI | NAAA 44/4885GAA 17/4885NFKB1 2947/4885 |
| US-20190100516-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | MGAM, ABCG2, SI | NAAA 44/4885GAA 17/4885NFKB1 2947/4885 |
| US-10815228-B2 | Aztreonam derivatives and uses thereof | MGAM, ABCG2, SI | NAAA 44/4885GAA 17/4885NFKB1 2947/4885 |
| US-20210009580-A1 | AZTREONAM DERIVATIVES AND USES THEREOF | MGAM, ABCG2, SI | NAAA 44/4885GAA 17/4885NFKB1 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.